MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 84 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $379,534 | -64.6% | 47,147 | -52.3% | 0.00% | – |
| Q2 2023 | $1,072,654 | +27.5% | 98,771 | -19.0% | 0.00% | – |
| Q1 2023 | $841,227 | +108.7% | 121,917 | +20.4% | 0.00% | – |
| Q4 2022 | $403,020 | +77.5% | 101,261 | +194.9% | 0.00% | – |
| Q3 2022 | $227,000 | -55.6% | 34,336 | -67.6% | 0.00% | – |
| Q2 2022 | $511,000 | +146.9% | 105,947 | +380.7% | 0.00% | – |
| Q1 2022 | $207,000 | -54.3% | 22,041 | -42.2% | 0.00% | – |
| Q4 2021 | $453,000 | +72.2% | 38,158 | +64.4% | 0.00% | – |
| Q3 2021 | $263,000 | -82.6% | 23,217 | -72.4% | 0.00% | – |
| Q2 2021 | $1,509,000 | +42.1% | 84,161 | +22.7% | 0.00% | – |
| Q1 2021 | $1,062,000 | +154.7% | 68,568 | +100.3% | 0.00% | – |
| Q4 2020 | $417,000 | +102.4% | 34,225 | +112.9% | 0.00% | – |
| Q3 2020 | $206,000 | – | 16,072 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |